Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis represents a focused update of the ANCA-Associated Vasculitis chapter from the KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. The aim is to assist clinicians caring for people with ANCA-associated vasculitis. The update takes into consideration evidence from randomized controlled trials published since February 2022. As in 2021, the chapter follows the same template providing guidance related to diagnosis, prognosis, treatment, and special situations. Based on the evidence, this update is mostly focused on guidance related to treatment of ANCA-associated vasculitis. Development of this guideline followed an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies, and appraisal of the certainty of the evidence and the strength of recommendations followed the “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach. Limitations of the evidence are discussed and areas of future research are also presented.

改善全球结局(KDIGO)2024临床实践指南抗中性粒细胞胞浆抗体(ANCA)相关血管炎的管理代表了KDIGO2021中ANCA相关血管炎章节的重点更新肾小球疾病管理的临床实践指南。目的是协助护理ANCA相关血管炎患者的临床医生。更新考虑了自2022年2月以来发表的随机对照试验的证据。与2021年一样，章节遵循相同的模板，提供与诊断、预后、治疗相关的指导，和特殊情况。基于证据，本次更新主要侧重于以下方面的指南治疗ANCA相关血管炎。本指导原则的制定遵循证据审查和评估过程。治疗方法和指南建议是基于相关研究的系统综述和证据确定性的评价建议的强度遵循“建议评估分级”，开发和评价”(GRADE)方法。讨论了证据的局限性，并还介绍了未来研究的领域。